Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.53 |
| ▸ | CCR2 | P41597 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
| ▸ | HTR7 | P34969 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779379 | 0.85 | CCR2 (0.58) | ADRA1DCCR2HTR2AHTR7DRD2 | |
| SCHEMBL9032327 | 0.84 | ADRA1D (0.69) | ADRA1DHTR2ADRD2KCNH2 | |
| Hydrochloric Acid SCHEMBL30908966 | 0.83 | ADRA1D (0.70) | ADRA1DHTR2ADRD2KCNH2 | |
| Hydrochloric Acid SCHEMBL9031744 | 0.81 | ADRA1D (0.64) | ADRA1DKDM4E | |
| Hydrochloric Acid SCHEMBL9030526 | 0.79 | ADRA1D (0.64) | ADRA1DCCR2 | |
| Hydrochloric Acid SCHEMBL9029640 | 0.79 | ADRA1D (0.64) | ADRA1DDRD2 | |
| Hydrochloric Acid SCHEMBL9031499 | 0.79 | ADRA1D (0.64) | ADRA1D | |
| Hydrochloric Acid SCHEMBL9029293 | 0.79 | ADRA1D (0.60) | ADRA1DHTR2AHTR7DRD2 | |
| SCHEMBL4058873 | 0.78 | HTR1F (0.40) | CCR2HTR2AKCNH2 | |
| SCHEMBL993093 | 0.78 | HTR2B (0.55) | POLBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1191246-C | Indolylpiperidine derivatives as antihistamines and antiallergic agents | ALMIRALL PRODESFARMA SA (ES) | 2005-03-02 | — | — | CN | claimed |
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | claimed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | claimed |
| JP-2003501424-A | — | — | 2003-01-14 | — | — | JP | claimed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | claimed |
| EP-1183251-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2002-03-06 | — | — | EP | claimed |
| WO-2000075130-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-12-14 | — | — | WO | claimed |
| CN-1191246-C | Indolylpiperidine derivatives as antihistamines and antiallergic agents | ALMIRALL PRODESFARMA SA (ES) | 2005-03-02 | — | — | CN | disclosed |
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | disclosed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | disclosed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | disclosed |
| CN-1368969-A | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA SA (ES) | 2002-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | ADRA1D 24/4885CCR2 1064/4885KDM4E 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.